Effectiveness & Implementation of a Behavioral Intervention for Adherence and Substance Use in HIV Care in South Africa
Hybrid Effectiveness-Implementation Trial for ART Adherence and Substance Use in HIV Care in South Africa
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- HIV positive and on ART
- 18-65 years of age
- Elevated substance use risk (ASSIST score greater than or equal to 4 for drugs or greater than or equal to 11 for alcohol)
Have at least one of the following:
- Not attained viral suppression from first line ART (VL>400 copies/mL)
- On second-line ART treatment
- Reinitiated first-line treatment within the past three months
- Had a pharmacy non-refill at least once in the past 3 months
Exclusion Criteria:
- Inability to provide informed consent or complete procedures in English or isiXhosa
- Severe risk/likely dependence for opiates (ASSIST score >26) because opiate substitution therapy may not be available
- Severe alcohol dependence symptoms that may warrant medical management of potential withdrawal symptoms
- Active, untreated, major mental illness (with untreated psychosis or mania) that would interfere with the paraprofessional adapted intervention
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Project Khanya
Those assigned to Project Khanya (the behavioral intervention for substance use and adherence condition) will have approximately 6 sessions (including Life-Steps, behavioral activation, and relapse prevention) delivered by a peer interventionist plus standard of care, which is typically referral to a local outpatient substance use treatment clinic.
They will also receive a Wisepill, a wireless, real-time adherence monitoring device.
|
This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
|
|
无干预:ESOC
Those assigned to the ESOC (enhanced standard of care) condition will receive the standard of care, which is referral to a local substance use treatment clinic.
The substance use clinics in the location that this study occurs follow the Matrix, and evidence-based 16-week outpatient program to treat substance use.
We will enhance patients' normal referral to Matrix for ESOC participants by promoting facilitating and following up on the referral.
Additionally, those in the control group will also receive a Wisepill, a wireless adherence monitoring device.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Changes in HIV Medication Adherence Throughout Intervention Phase
大体时间:Assessed between baseline assessment and the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
Percentage of prescribed antiviral therapy agent (medications) taken as measured by real time wireless motoring device
|
Assessed between baseline assessment and the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
|
Biological Measure of Substance Use
大体时间:Assessed at the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
Substance use measured with urinalysis.
|
Assessed at the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
|
Biological Measure of Substance Use
大体时间:Assessed at the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
Substance use measured with phosphatidylethanol (PEth) concentration, which is an objective biomarker of alcohol use that can detect blood collected up to 21 days after alcohol consumption.
Minimum detection value is 8 ng/mL.
Higher PEth values indicate greater concentration of alcohol.
Values of ≥ 50 ng/mL indicate unhealthy drinking.
|
Assessed at the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
|
Changes in Self-reported Substance Use
大体时间:Assessed between baseline assessment and the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
World Health Organization Alcohol, Smoking, and Substance Involvement Screening Test (WHO-ASSIST).
It is a measure used to assess substance use risk for alcohol, cannabis, cocaine, opiates, and amphetamines, hallucinogens, and other drugs.
Standardized cutoff scores are used to categorize risk levels: low risk (0-3 for illicit drugs/0-10 for alcohol), moderate risk (4-26 for illicit drugs/11-26 for alcohol), or high risk (> 26) for substance use-related problems.
|
Assessed between baseline assessment and the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Biological Measure of Substance Use
大体时间:Assessed at follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
Substance use measured with urinalysis.
|
Assessed at follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
|
Biological Measure of Substance Use
大体时间:Assessed at follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
Substance use measured with phosphatidylethanol (PEth) concentration, which is an objective biomarker of alcohol use that can detect blood collected up to 21 days after alcohol consumption.
Minimum detection value is 8 ng/mL.
Higher PEth values indicate greater concentration of alcohol.
Values of ≥ 50 ng/mL indicate unhealthy drinking.
|
Assessed at follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
|
Changes in Self-reported Substance Use
大体时间:Assessed between baseline assessment and follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
World Health Organization Alcohol, Smoking, and Substance Involvement Screening Test (WHO-ASSIST).
It is a measure used to assess substance use risk for alcohol, cannabis, cocaine, opiates, and amphetamines, hallucinogens, and other drugs.
Standardized cutoff scores are used to categorize risk levels: low risk (0-3 for illicit drugs/0-10 for alcohol), moderate risk (4-26 for illicit drugs/11-26 for alcohol), or high risk (> 26) for substance use-related problems.
|
Assessed between baseline assessment and follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
|
Intervention Acceptability
大体时间:Assessed at the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
15-item acceptability subscale of a pragmatic, quantitative assessment based on RE-AIM developed by the Applied Mental Health Research group (AMHR) at Johns Hopkins University. Total scores are averaged across all items and range from 0 to 3. Higher scores indicate greater acceptability. Qualitative interviews will also be conducted with intervention participants at the end of the study to assess acceptability guided by RE-AIM and the Proctor model. |
Assessed at the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
|
Intervention Feasibility
大体时间:Assessed at the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
14-item feasibility subscale of a pragmatic, quantitative assessment based on RE-AIM developed by the Applied Mental Health Research group (AMHR) at Johns Hopkins University. Total scores are averaged across all items and range from 0 to 3. Higher scores indicate greater feasibility. Qualitative interviews will also be conducted with intervention participants at the end of the study to assess feasibility guided by RE-AIM and the Proctor model. |
Assessed at the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
|
Intervention Fidelity
大体时间:Assessed between randomization and the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
Independent fidelity ratings of a randomly selected subset (20%) of intervention sessions using a fidelity assessment developed for each session that includes 15-19 items that map onto each core intervention component, and factors unique to the peer delivery implementation strategy (i.e., appropriate self-disclosure, stigmatizing behaviors, common factors including warmth and non-judgment).
|
Assessed between randomization and the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
|
Intervention Uptake
大体时间:Assessed between randomization and the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
Intervention participant attendance and retention (i.e., the mean number of intervention sessions attended by intervention participants)
|
Assessed between randomization and the acute outcome (approximately 12-weeks post-randomization/ post-intervention assessment)
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
HIV Viral Load
大体时间:Assessed at follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
Percentage of patients with a suppressed viral load (<400 copies/ml)
|
Assessed at follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
|
Changes in Self-reported Substance Use
大体时间:Assessed between baseline assessment and follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
Changes in percent days used any substance measured by timeline follow-back
|
Assessed between baseline assessment and follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
|
Changes in Self-reported Substance Use
大体时间:Assessed between baseline assessment and follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
Changes in number of drinks measured by timeline follow-back
|
Assessed between baseline assessment and follow-up (approximately 24-weeks post-randomization/ 6-month follow-up assessment)
|
合作者和调查者
出版物和有用的链接
一般刊物
- Belus JM, Rose AL, Andersen LS, Ciya N, Joska JA, Myers B, Safren SA, Magidson JF. Adapting a Behavioral Intervention for Alcohol Use and HIV Medication Adherence for Lay Counselor Delivery in Cape Town, South Africa: A Case Series. Cogn Behav Pract. 2022 May;29(2):454-467. doi: 10.1016/j.cbpra.2020.10.003. Epub 2020 Nov 10.
- Belus JM, Joska JA, Bronsteyn Y, Rose AL, Andersen LS, Regenauer KS, Myers B, Hahn JA, Orrell C, Safren SA, Magidson JF. Gender Moderates Results of a Randomized Clinical Trial for the Khanya Intervention for Substance Use and ART Adherence in HIV Care in South Africa. AIDS Behav. 2022 Nov;26(11):3630-3641. doi: 10.1007/s10461-022-03765-8. Epub 2022 Jul 27.
- Magidson JF, Joska JA, Belus JM, Andersen LS, Regenauer KS, Rose AL, Myers B, Majokweni S, O'Cleirigh C, Safren SA. Project Khanya: results from a pilot randomized type 1 hybrid effectiveness-implementation trial of a peer-delivered behavioural intervention for ART adherence and substance use in HIV care in South Africa. J Int AIDS Soc. 2021 Jun;24 Suppl 2:e25720. doi: 10.1002/jia2.25720.
- Magidson JF, Joska JA, Myers B, Belus JM, Regenauer KS, Andersen LS, Majokweni S, O'Cleirigh C, Safren SA. Project Khanya: a randomized, hybrid effectiveness-implementation trial of a peer-delivered behavioral intervention for ART adherence and substance use in Cape Town, South Africa. Implement Sci Commun. 2020;1:23. doi: 10.1186/s43058-020-00004-w. Epub 2020 Mar 4.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 187/2018
- K23DA041901 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.